Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441727 · ClinicalTrials.gov registry record · Phase 3
Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,426
- Enrollment target
NCT00441727 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 2,426 participants.
The verdict
NCT00441727, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,426 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.
Interventions
- DRUG Placebo
- DRUG Esomeprazole 40 mg
- DRUG Esomeprazole 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,426 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441727
The ClinicalTrials.gov registry entry for NCT00441727 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00441727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441727 about?
NCT00441727 is a clinical study titled "Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)". The purpose of this study is to compare the effect of esomeprazole 20 or 40 mg once daily versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low-dose acetylsalicylic acid.
What is the current status of trial NCT00441727?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,426 participants. The study started on 2007-02. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00441727?
The interventions under investigation include: Placebo (DRUG), Esomeprazole 40 mg (DRUG), Esomeprazole 20 mg (DRUG).
Who is sponsoring clinical trial NCT00441727?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.